

## Change of AGM Date

**1 September 2025 – Melbourne, Australia:** Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that the date of the Company’s 2025 Annual General Meeting (**AGM**) has been changed to Wednesday, 26 November 2025. The revised timing ensures shareholders are better informed, with sufficient time to review and consider recent developments (clinical, regulatory, and corporate) ahead of the meeting, enabling more constructive engagement at the AGM. The Board looks forward to meeting shareholders at the AGM.

In accordance with ASX Listing Rule 3.13.1 and rule 7.2(f)(ii) of the Company’s Constitution, the Company advises that the Closing Date for receipt of nominations for the position of Director is Wednesday, 8 October 2025. Any nominations must be received in writing no later than 5.00pm (Melbourne time) on Wednesday, 8 October 2025 at the Company’s registered office.

The Company notes that the deadline for nominations for the position of Director is separate to voting on Director elections. Details of the Director’s to be elected will be provided in the Company’s Notice of AGM in due course.

Shareholders will be advised of further details regarding the AGM in the Notice of Meeting, which will be despatched to shareholders in due course.

-ENDS-

This announcement has been authorized for release on behalf of the Neurizon Board by:  
Sergio Duchini, Chairman.

For further information, please contact:

**Dr. Michael Thurn**

Managing Director and Chief Executive Officer  
Neurizon Therapeutics Limited  
[enquiries@neurizon.com](mailto:enquiries@neurizon.com)  
+61 (3) 9692 7222

**Lidija Damjanovic**

Head of Marketing and Corporate Affairs  
Neurizon Therapeutics Limited  
[lidija@neurizon.com](mailto:lidija@neurizon.com)  
+61 (0) 425 700 504

**Released through:** Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

### About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

### Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit  
<https://investorhub.neurizon.com>

